Source comparison
Growth Hormone Peptides 2026 Update: Product Comparison
CJC-1295 (DAC) GHRH analog with drug affinity complex ~6–8 days Long-acting GH release studies 2–8°C, lyophilised or reconstituted 503B-compoundable, Category 2 Ipamorelin Selective GHSR-1a agonist ~2 hours Pulsatile GH secretion research 2–8°C, use within 28
This comparison does not assign a generated winner or score.
- CJC-1295 (DAC)
- GHRH analog with drug affinity complex
- ~6–8 days
- Long-acting GH release studies
- 2–8°C, lyophilised or reconstituted
- 503B-compoundable, Category 2
- Ipamorelin
- Selective GHSR-1a agonist
- ~2 hours
- Pulsatile GH secretion research
- 2–8°C, use within 28 days reconstituted
- 503B-compoundable, widely available
- MK-677 (Ibutamoren)
- Oral ghrelin mimetic
- ~24 hours
- Chronic GH elevation models
- Room temperature, oral formulation
- Non-peptide, not FDA-approved; research-grade available
- Hexarelin
- High-affinity GHSR-1a agonist
- ~70 minutes
- Acute GH pulse studies
- 2–8°C, degrades rapidly once mixed
- 503B-compoundable, limited suppliers
- Tesamorelin
- GHRH analog (44 amino acids)
- ~26–38 minutes
- Lipodystrophy, metabolic research
- −20°C lyophilised, 2–8°C reconstituted
- FDA-approved (Egrifta), research protocols require IND
- LUM-201 (investigational)
- Novel GHRH analog
- ~8 hours
- Phase 2 GHD trials
- Data pending commercial release
- Investigational New Drug only